NicOx: a 'super aspirin' versus infarction

The 'super aspirin' of NicOx, a Sophipolitan firm, may reduce infarctions. This is the result of a study realized by an English university and recently presented during the British Pharmacology Society meeting. The NO-aspirin, a drug liberating nitric oxide, NicOx is finalizing, has been tested on a pig. Given highly measured out, it 'reduces the size of the infarction, while aspirin does not have any effect', a release announced.

'The new data indicate the molecule has a wide activity spectrum at cardiovascular level, and possibilities highly superior to aspirin's', Michèle Garufi concluded, NicOx CEO. The clinical development would begin in 2001.